Suppression of IL‐12/IL‐23 p40 subunit in the skin and blood of psoriasis patients by Tofacitinib is dependent on active interferon‐γ signaling in dendritic cells: Implications for the treatment of psoriasis and interferon‐driven diseases

Interleukin (IL)‐12 and IL‐23 are pro‐inflammatory cytokines produced by dendritic cells (DCs) and associated with Psoriasis (Pso) and Psoriatic Arthritis (PsA) pathogenesis. Tofacitinib, a Janus kinase inhibitor, effectively suppresses inflammatory cascades downstream the IL‐12/IL‐23 axis in Pso an...

Descripción completa

Detalles Bibliográficos
Autores principales: Vincken, Nanette L. A., Welsing, Paco M. J., Silva‐Cardoso, Sandra C., Bekker, Cornelis P. J., Lopes, Ana P., Olde Nordkamp, Michel, Leijten, Emmerik F. A., Radstake, Timothy R. D. J., Angiolilli, Chiara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Concise Communications
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313893/
https://www.ncbi.nlm.nih.gov/pubmed/35297512
http://dx.doi.org/10.1111/exd.14566

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313893/
https://www.ncbi.nlm.nih.gov/pubmed/35297512
http://dx.doi.org/10.1111/exd.14566

Ejemplares similares